Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GRN | P28799 | 2/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5109059 | 0.89 | POLB (0.41) | POLBSMN1; SMN2MAPK1TDP1HTR2A | |
| SCHEMBL7997757 | 0.82 | KDM4E (0.54) | POLBSMN1; SMN2SLC6A4ALDH1A1 | |
| SCHEMBL5120275 | 0.82 | PPARG (0.48) | POLBSMN1; SMN2MEN1KMT2AGRN | |
| SCHEMBL8428544 | 0.77 | PTGS2 (0.46) | POLBMEN1KMT2A | |
| SCHEMBL5110194 | 0.77 | CYP11B1 (0.43) | POLBSMN1; SMN2TDP1HTR2AHTR2C | |
| SCHEMBL4914763 | 0.76 | SMN1; SMN2 (0.41) | POLBSMN1; SMN2MAPK1TDP1HTR2A | |
| SCHEMBL4916492 | 0.76 | SMN1; SMN2 (0.56) | POLBSMN1; SMN2MAPK1TDP1MEN1 | |
| SCHEMBL13373557 | 0.75 | HTR2C (0.56) | POLBSMN1; SMN2MAPK1TDP1HTR2A | |
| SCHEMBL7998018 | 0.75 | GRN (0.48) | POLBSMN1; SMN2TDP1SLC6A4ALDH1A1 | |
| SCHEMBL5105836 | 0.72 | ALDH1A1 (0.47) | POLBSMN1; SMN2MAPK1TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20050009894-A1 | Benzimidazole derivatives and their use as KDR kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2005-01-13 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| EP-1442034-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS KDR PROTEIN KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003035644-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS KDR PROTEIN KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | POLB 2261/4885SMN1; SMN2 4210/4885MAPK1 154/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | POLB 2841/4885SMN1; SMN2 3516/4885MAPK1 23/4885 |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | KDR, MUSK, FLT4 | POLB 2745/4885SMN1; SMN2 1094/4885MAPK1 125/4885 |
| US-20050009894-A1 | Benzimidazole derivatives and their use as KDR kinase protein inhibitors | KDR, MUSK, FLT4 | POLB 2789/4885SMN1; SMN2 1091/4885MAPK1 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.